Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | METAP2 | P50579 | 1/20 | 0.65 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192733 | 0.89 | KMT2A (0.67) | KMT2ACA1CA9HPGDGAA | |
| SCHEMBL31680569 | 0.88 | KMT2A (0.89) | KMT2AHPGDGAALMNAL3MBTL1 | |
| SCHEMBL11901003 | 0.88 | KMT2A (0.89) | KMT2AHPGDGAALMNAL3MBTL1 | |
| SCHEMBL12472363 | 0.86 | KMT2A (0.72) | KMT2ACA1CA9HPGDLMNA | |
| SCHEMBL13812768 | 0.86 | LIPG (0.62) | KMT2ACA1CA9HPGDGAA | |
| SCHEMBL8635709 | 0.83 | KMT2A (1.00) | KMT2AHPGDGAALMNAL3MBTL1 | |
| SCHEMBL1984940 | 0.83 | KMT2A (1.00) | KMT2AHPGDGAALMNAL3MBTL1 | |
| SCHEMBL2267873 | 0.83 | HSP90AA1 (0.64) | KMT2ACA1CA9HPGDGAA | |
| SCHEMBL8404892 | 0.82 | NPC1 (0.62) | KMT2ACA1CA9NPC1APEX1 | |
| SCHEMBL1543219 | 0.82 | ALDH1A1 (0.57) | KMT2ACA1CA9HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115487316-B | Potassium ion selective filter membrane/magnetic mesoporous nanocomposite, fluorescence/magnetic resonance dual-mode imaging probe and application | 浙江大学 | 2024-06-07 | — | — | CN | claimed |
| CN-109876157-A | Ion specificity filter membrane/mesoporous silicon composite material, nano-sensor and products thereof and application | 浙江大学 | 2019-06-14 | — | — | CN | claimed |
| CN-101932325-A | Ido inhibitors | NEWLINK GENETICS | 2010-12-29 | — | — | CN | claimed |
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | claimed |
| WO-2007047579-A2 | A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| CN-119424687-A | Brain-targeted neuron ion signal specific bimodal nanoprobe, preparation method and application | 上海交通大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-115487316-B | Potassium ion selective filter membrane/magnetic mesoporous nanocomposite, fluorescence/magnetic resonance dual-mode imaging probe and application | 浙江大学 | 2024-06-07 | — | — | CN | disclosed |
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| CN-115487316-A | Potassium ion selective filter membrane/magnetic mesoporous nanocomposite material, fluorescence/magnetic resonance bimodal imaging probe and application | 浙江大学 | 2022-12-20 | — | — | CN | disclosed |
| EP-4093401-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | The Board of Regents of the University of Texas System (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11421049-B2 | Photopolymerization synergist | Piedmont Chemical Industries, LLC (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2021151104-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-2018166-A2 | TEREPHTHALAMATE COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS HIV INTEGRASE INHIBITORS | IRM LLC (BM) | 2009-01-28 | — | — | EP | disclosed |
| WO-2008073138-A2 | TEREPHTHALAMATE COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS HIV INTEGRASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073138-A2 | TEREPHTHALAMATE COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS HIV INTEGRASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
| EP-1809332-A2 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | Oncologic, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | disclosed |
| US-20060018908-A1 | Compositions and methods for treating cancer | ROSE, DAVID STUART | 2006-01-26 | — | — | US | disclosed |
| WO-2006010165-A2 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | ONCOLOGIC, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050058652-A1 | Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer | ROSE, DAVID STUART | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | EIF2AK2, SARS1, ACE | KMT2A 1142/4885CA1 2072/4885CA9 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.